ORIGINAL RESEARCH

Sacubitril/valsartan Compared to Valsartan in Regressing Myocardial Fibrosis in Hypertensive Heart Disease: The REVERSE-LVH Randomized Phase 2 Trial

Brief Title: Myocardial Fibrosis and Hypertrophy Regression

Vivian Lee, MSc,[a]* Mayank Dalakoti, MD,[b]* Qishi Zheng, MBBS, MPhil, MSc[c] Desiree-Faye Toh, MSc,[a] Redha Boubertakh, PhD[a] Jennifer A Bryant, PhD[d], Tar-Choon Aw, MBBS[e], Chi-Hang Lee, MBChB, MD[b] A Mark Richards, MBChB, MD, PhD[f], Javed Butler, MD, MPH, MBA[g,h], Javier Díez, MD, PhD[I, j], Roger Foo, MD[b,k], Stuart A Cook, MBBS, PhD[a,d,l], Carolyn SP Lam, MBBS, PhD[a,d,l], Thu-Thao Le, MSc, PhD[a,m]*, Calvin WL Chin, MD, PhD[a,d,m]*

*Equal contributions as co-authors

Affiliations

[a]National Heart Research Institute of Singapore, National Heart Centre Singapore, Singapore, Singapore

[b]Department of Cardiology, National University Heart Centre Singapore, National University Health System, Singapore, Singapore

[c]Cochrane Singapore, Singapore, Singapore

[d]Department of Cardiology, National Heart Centre Singapore, Singapore, Singapore

[e]Department of Laboratory Medicine, Changi General Hospital, Singapore, Singapore

[f]Christchurch Heart Institute, University of Otago, Christchurch, New Zealand

[g]Baylor Scott and White Research Institute, Dallas, Texas, United States

[h]Department of Medicine, University of Mississippi School of Medicine, Mississippi, United States

[i]Centre of Applied Medical Research (CIMA) and School of Medicine, University of Navarra, Pamplona, Spain

[j]Centre for Network Biomedical Research of Cardiovascular Diseases (CIBERCV), Carlos III Institute of Health, Madrid, Spain

[k]Cardiovascular Metabolic Disease Translational Research Program, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore

[l]Cardiovascular & Metabolic Disorders SRP, Duke-NUS Medical School, Singapore, Singapore

[m]Cardiovascular Academic Clinical Program (ACP), Duke-NUS Medical School, Singapore, Singapore

Address for Correspondence

Dr Calvin Chin
Department of Cardiology
5 Hospital Drive, Singapore 169609
Email: gmsccwl@nus.edu.sg
Phone: (65) 6704 8905
Fax: (65) 6844 9030

NUS Restricted

Word Count: 6365
4 Figures and 3 Tables

NUS Restricted

ABSTRACT

BACKGROUND

Diffuse interstitial fibrosis is a potential therapeutic target because of its prognostic significance and reversibility. Sacubitril/valsartan may offer superior anti-fibrotic effects through its dual inhibition of neprilysin and angiotensin receptors. REVERSE-LVH compared the efficacy of sacubitril/valsartan versus valsartan in reduction of diffuse interstitial fibrosis in patients with essential hypertension and left ventricular hypertrophy (LVH), independent of blood pressure (BP) reduction.

METHODS

Hypertensive participants with LVH (n=78; 58±11 years) were randomized to receive sacubitril/valsartan or valsartan for 52 weeks. Primary endpoint was an absolute reduction in interstitial volume (extracellular volume fraction × myocardial volume) from baseline to post-treatment, using cardiovascular magnetic resonance (CMR).

RESULTS

The mean 24h systolic BP at week 52 was similar between sacubitril/valsartan and valsartan (125±11 and 126±11mmHg, respectively; no treatment difference between groups; P=0.379). The absolute reduction in interstitial volume was greater with sacubitril/valsartan compared to valsartan (**unindexed**: -5.2±5.4 versus -2.5±3.1 mL, P=0.006; **indexed to body surface area**: -2.7±2.3 versus -1.4±1.8 mL/m^2, P=0.008). In pre-specified secondary endpoints, sacubitril/valsartan demonstrated superior reduction in LV mass, left atrial volume and estimated LV filling pressure compared to valsartan (P<0.02 for all). Compared to valsartan,

NUS Restricted

sacubitril/valsartan was associated with a significant reduction in NT-proBNP and high-sensitivity cardiac troponin T concentrations.

CONCLUSIONS

Despite similar BP reduction, sacubitril/valsartan led to greater regression in diffuse interstitial fibrosis compared to valsartan in hypertensive LVH. This was associated with reduction in LV mass; and improvement in diastolic function and circulating cardiac markers. These findings suggest potential for regressing diffuse interstitial fibrosis in patients with hypertensive LVH through accessible and well-tolerated pharmacological interventions, beyond BP control.

KEYWORDS

Diffuse interstitial fibrosis; cardiovascular magnetic resonance; hypertensive heart disease

NUS Restricted

ABBREVIATIONS

ACEI = Angiotensin-converting enzyme inhibitor

ARB = Angiotensin receptor blocker

ARNI = Angiotensin receptor-neprilysin inhibitor

BP = Blood pressure

CMR = Cardiovascular magnetic resonance

ECV = Extracellular volume

HF = Heart failure

HHD = Hypertensive heart disease

LVH = Left ventricular hypertrophy

RAAS = Renin-angiotensin-aldosterone system

NUS Restricted

INTRODUCTION

About 30% of the burden related to hypertension occurred in individuals with well-controlled blood pressures (BP)[1]. The updated definition of heart failure (HF) stages had identified more asymptomatic individuals in a pre-clinical stage[2]. This suggests that despite substantial benefits associated with BP lowering, there remains opportunities to improve risk stratification and develop therapeutic options beyond managing peripheral BP to slow/prevent the development of symptomatic HF.

In hypertensive heat disease (HHD), left ventricular hypertrophy (LVH) occurs in response to hemodynamic and neuro-hormonal stresses triggered by prolonged exposure to elevated BP[3]. Its pathophysiology is accompanied by an expansion in extracellular volume (ECV) due to accumulation of extracellular matrix components and collagen deposition throughout the myocardium. Initially reversible, diffuse interstitial fibrosis progresses to irreversible focal replacement fibrosis because of worsening cardiomyocyte injury and death[4]. Myocardial fibrosis significantly contributes to cardiac dysfunction, arrhythmias, and reduced coronary perfusion, ultimately leading to HF and adverse cardiovascular outcomes[4,5]. Therefore in addition to peripheral BP, diffuse interstitial fibrosis is a potential marker for enhancing risk stratification and directing targeted therapies to prevent the progression of hypertensive LVH to advanced HF stages.

Angiotensin receptor–neprilysin inhibitor (ARNI) represents a novel drug class that inhibits the renin-angiotensin-aldosterone system (RAAS) and enhances natriuretic peptides. This dual agent combines a neprilysin inhibitor (sacubitril) and an angiotensin receptor blocker (ARB; valsartan). Sacubitril/valsartan has shown superior benefits over conventional ARB or angiotensin-converting enzyme inhibitors (ACEI) monotherapy in lowering BP and

NUS Restricted

improving outcomes in those with HF and reduced LV ejection fraction (HFrEF)[6,7]. Pre-clinical studies of mouse models have demonstrated that sacubitril/valsartan is effective in reducing myocardial fibrosis and improving cardiac function by attenuating angiotensin II and transforming growth factor β1 fibrotic pathways[8,9].

Using cardiovascular magnetic resonance (CMR) to quantify interstitial volume as a measure of diffuse interstitial fibrosis non-invasively[10], the aim of the study was to compare sacubitril/valsartan versus valsartan in reducing diffuse interstitial fibrosis in patients with hypertensive LVH. The hypothesis was that 52 weeks of sacubitril/valsartan therapy would result in greater regression of diffuse interstitial fibrosis compared to valsartan, independent of BP control.

METHODS

Trial Design

The Role of ARNI in the Ventricular Remodeling in Hypertensive LVH (REVERSE-LVH) was a prospective, randomized, open-label, blinded endpoint (PROBE) phase 2 trial (ClinicalTrials.gov identifier: NCT03553810). The original design and methods of the trial has been published[11]. All study procedures were conducted at the National Heart Centre Singapore (NHCS). This was an investigator-initiated trial. All trial-related expenses, including investigations and medications were funded by the National Medical Research Council. Novartis did not participate in the design of the trial, analysis and interpretation of the data.

NUS Restricted

REVERSE-LVH was reviewed and approved by the SingHealth Centralized Institutional Review Board (CIRB ref: 2018/2182) and the Health Sciences Authority. All participants provided written informed consent.

Trial Participants and Recruitment

Participants were recruited between June 2019 and June 2023. These participants were screened and recruited from the REMODEL cohort, an ongoing non-interventional prospective study to examine the role of CMR in patients with hypertension (ClinicalTrials.gov Identifier: NCT02670031). Eligible participants were adults at least 21 years old with essential hypertension and LVH, diagnosed using Asian specific thresholds on CMR[12].

Essential hypertension was defined as systolic BP (SBP) ≥140 mmHg and/or diastolic BP (DBP) ≥90 mmHg at time of diagnosis, on at least one medication for BP control. Individuals with known secondary causes of hypertension, inherited cardiomyopathies, atrial fibrillation, and history of cardiovascular complications (such as myocardial infarction, HF and stroke) were excluded. Other exclusion criteria included intolerance to ARBs, contraindications for CMR, stage IV or V chronic renal disease, presence of disease with limited life expectancy (<3 years), pregnancy and/or breast-feeding.

Randomization, Treatment and Blinding

Study participants were randomized to either sacubitril/valsartan or valsartan in a 1:1 fashion. Randomization was performed using sealed and sequentially numbered envelopes, prepared by the Singapore Clinical Research Institute. Crossover of treatment allocation was not allowed, and the treatment duration was 52 weeks. Treatment allocation was not concealed

NUS Restricted

from patients. Treatment assignment and trial endpoints were concealed from the core-lab staff analyzing the CMR images.

Sacubitril/valsartan was initiated at 50-100mg twice a day, uptitrated to maximum 200mg twice a day; valsartan was initiated at 80-160mg once a day, uptitrated to maximum 320 mg once a day. Medications in both treatment groups were uptitrated as tolerated to achieve a target SBP of <140 mmHg according to contemporary guidelines at the time of study conception[13,14]. Additional non-RAAS inhibiting anti-hypertensive agents were prescribed where necessary. Participants who were on ACEI or ARB at the time of enrollment underwent a washout period of two weeks before commencing trial medication to eliminate residual RAAS-intervening effects, during which alternative medicines or uptitration of existing concomitant anti-hypertensive agents were prescribed for BP control.

Study medications were dispensed by NHCS pharmacists after each study visit. Treatment adherence was assessed by pill counting by the pharmacists.

Study Procedures

Baseline demographic and clinical information were obtained from participants upon randomization. Participants were seen at the clinic with 24h ambulatory BP at weeks 4, 8, 26 and 52. Renal function tests were performed during these visits as part of safety monitoring. Phone calls were made to the participants at weeks 12 and 38. Additional un-scheduled visits were arranged if deemed necessary by the study team (**Supplemental Table 1**). If withdrawal of participation occurred after 12 weeks of treatment allocation, final visit procedures (including CMR to assess endpoints) would be performed at the time of withdrawal. At each clinic visit, adverse events related to study treatment were assessed by the study team. If

NUS Restricted

present, they were recorded and reported to the local ethics board and the Health Sciences Authority within the required timeline.

Cardiac volumes, function, myocardial mass, and interstitial volumes were assessed at baseline and after 52 weeks of treatment using standardized imaging CMR protocols on the Siemens Aera 1.5T scanner (Siemens Healthineers, Erlangen, Germany). Balanced steady-state free precession cine images were acquired in the long-axis 2-, 3- and 4-chamber views; and short axis cines extending from the mitral valve annulus to the apex (acquired voxel size of $1.6 \times 1.3 \times 8.0$ mm^3 and 30 phases per cardiac cycle). T1 mapping was performed with the Modified Look-Locker Inversion-recovery sequence, where native T1 maps were acquired using a heartbeat scheme of 5(3)3, and post-contrast T1 maps were acquired 15 minutes after administration of 0.1 mmol/kg gadobutrol (Gadovist; Bayer Pharma AG, Germany) using a heartbeat scheme of 4(1)3(1)2. Details of the imaging protocol were published in the trial protocol[11].

All CMR images were de-identified and analyzed by trained personnel at the National Heart Research Institute Singapore CMR core-lab using CVI42 software (Circle Cardiovascular Imaging, Calgary, Canada) according to the published analysis protocols[12,15].

Primary Trial Endpoint

The primary endpoint was the difference in absolute change in interstitial volume from baseline to post-treatment between the two treatment groups. Interstitial volume, reflecting diffuse interstitial fibrosis in the absence of infiltrative diseases, was derived as the product of ECV fraction × myocardial volume. This approach of quantifying interstitial volume was

NUS Restricted

previously validated against histological fibrosis[10] and demonstrated prognostic value in patients with HHD[16].

ECV fraction was measured using the T1 mapping module in CVI42. Hematocrit for calculating ECV fraction was taken on the day of CMR. Myocardial volume (mL) was calculated as myocardial mass (g) divided by the specific density of the myocardium (1.05 g/mL).

Secondary Trial Endpoints

Secondary endpoints were absolute change in CMR markers of cardiac remodeling that included LV morphology, function (including multi-directional LV strain) and mechanics. LV concentricity was defined by the ratio between LV mass and end-diastolic volume (EDV). Myocyte volume was derived as the product of (1-ECV fraction) × myocardial volume. Maximal left atrial volume was estimated based on the biplane area-length method using the 2- and 4-chamber views, at end atrial diastole[12].

Several CMR measures of myocardial mechanics were assessed. The Remodeling Index (RI) was used as a marker of LV wall stress[15,17]. The RI was calculated as $\frac{\sqrt[3]{EDV}}{t}$, where t is the maximal wall thickness (cm) across the 16 myocardial segments. The ventricular-arterial coupling ratio (VCR) was used to describe the relationship between LV and arterial system. It was calculated as the ratio of LV end-systolic volume to stroke volume[18]. LV filling pressures were estimated using a CMR model consisting of left atrial (LA) volume and LV mass, which had been validated with invasively measured pulmonary wedge pressure and demonstrated to have prognostic implications[19].

NUS Restricted

Blood samples were collected on the first and final study visit; and stored at −80°C. Biochemical analyses were conducted in a single freeze-thaw cycle across two assay runs at a College of American Pathologists-accredited laboratory (Changi General Hospital, Singapore). Serum NT-proBNP (N-terminal pro-B-type natriuretic peptide; proBNP II STAT, Roche Diagnostics, Germany) and hsTnT (high-sensitivity cardiac troponin T; Trop T hs STAT; Roche Diagnostics, Germany) were measured using electrochemiluminescence immunoassay on the Cobas E801 analyzer (Roche Diagnostics Asia Pacific, Singapore). The lab-reported lower detection limits for NT-proBNP and hsTnT were 11 pg/mL and 3 pg/mL, respectively. All biochemical concentrations below detection thresholds were assigned a value of half the detection limit.

Sample Size Estimation

An estimated sample size of 70 (35 per treatment group) would provide effective power of 80% at a 5% significance level (two-sided) to detect superiority of sacubitril/valsartan over valsartan for the primary endpoint, assuming an absolute minimum difference of 3.5 mL/m^2 in mean interstitial volume change between the two groups, a standard deviation (SD) of 5.8mL/m^2 (data subsequently published[17]) and a moderate correlation of 0.60 between interstitial volume at baseline and week 52. This effect size was based on an estimate of the magnitude of myocardial fibrosis regression that could be expected to translate into improved cardiac function and clinical outcomes[8]. The study plan was to recruit 80 participants, allowing a withdrawal rate of up to 15%.

Statistical Analysis

The endpoint comparison was based on intention-to-treat analysis, i.e., all participants were analyzed as part of the group to which they had been randomized. Continuous variables were

NUS Restricted

presented as mean ± SD and categorical variables were expressed as count (percentage). Skewed data were presented as medians and inter-quartile range. Comparisons between treatment groups were performed using independent samples t-tests for continuous variables and χ^2 test for dichotomous variables.

For primary endpoint, analysis-of-covariance (ANCOVA) was performed to adjust for baseline covariates. Treatment group at randomization was included as fixed effect. Baseline interstitial volume and 24h SBP were included as covariates. Results were reported as adjusted mean difference with 95% confidence intervals (CI). Post-hoc subgroup analyses of the primary endpoint were performed using two-way analysis of variance (ANOVA) to test heterogeneity of treatment effects in the following subgroups: age, sex, body mass index, whether washout was performed, LV ejection fraction, interstitial volume and 24h SBP. Continuous covariates were categorized by median values. The hypothesis testing on secondary endpoints was considered exploratory. The analyses were presented with effect estimates and unadjusted 95% CI. Adjustment for multiple comparisons was not performed.

The change in NT-proBNP and hsTnT were reported as the ratio of geometric mean values at baseline and 52 weeks. For treatment comparisons, the effective treatment ratio (ETR) was calculated as the ratio of geometric mean changes in biomarkers between the two groups.

Statistical significance was set at P value <0.05. All analyses were performed with SPSS, version 24 (SPSS; IBM, INC, Armonk, NY) and R, version 4.3.3 (R foundation for statistical computing, Vienna, Austria). Graphs were created using GraphPad Prism 8.1.2 (GraphPad Software, Inc, San Diego, CA). Statistical analyses were performed by team members who were not involved in image analysis and participants' follow up.

NUS Restricted

RESULTS

Study Participants

A total of 80 patients were recruited, and 78 individuals were successfully randomized to sacubitril/valsartan (n=39) and valsartan (n=39) (**Figure 1**). The mean age at baseline was 58±11 years, and 32 (41%) were males. The baseline 24h mean SBP and DBP were 137±14 and 81±11 mmHg, respectively. The baseline clinical, renal function and CMR characteristics were well-balanced between the two treatment groups (**Table 1**).

The median dose prescribed in the sacubitril/valsartan group was 200 [100, 200] mg twice a day and 160 [160, 320] mg once a day in the valsartan group, respectively. A total of 50 participants required additional anti-hypertensive medications (sacubitril/valsartan group, n=26 and valsartan group, n=24; P=0.571; **Supplemental Table 2**). The overall treatment adherence rate achieved in the trial was 97% (sacubitril/valsartan group, 97%; valsartan group, 96%).

Primary Trial Endpoint

The baseline interstitial volume in the sacubitril/valsartan group was 29.2±12.8 compared to 28.0±11.3 mL in the valsartan group. After 52 weeks, sacubitril/valsartan resulted in greater regression in diffuse interstitial fibrosis compared to valsartan alone (-5.2±5.4 versus -2.5±3.1 mL, P=0.006), with an absolute between-group difference of -2.8 (95% CI: -4.8 to -0.8) mL. Similar findings were observed when interstitial volume was indexed to body surface area (-2.7±2.3 versus -1.4±1.8 mL/m^2, P=0.008), with an absolute between-group difference of -1.3 (95% CI: -2.3 to -0.4) mL/m^2. Sacubitril/valsartan resulted in an 18% reduction in interstitial volume from baseline, compared to an 8.9% reduction with valsartan.

NUS Restricted

The reduction in diffuse interstitial fibrosis remained greater in the sacubitril/valsartan group compared to valsartan alone after accounting for baseline interstitial volume and baseline 24h SBP (**Figure 2**).

Exploratory subgroup analysis suggested treatment heterogeneity in favor of sacubitril/valsartan in individuals with 24h median SBP >135 mmHg, with an absolute between-group difference of -5.2 (95% CI: -8.0 to -2.5) mL/m^2 compared to -0.5 (95% CI: -3.2 to 2.2) mL/m^2 in those with 24h SBP ≤ 135 mmHg (P=0.016 for interaction). There was no significant treatment heterogeneity in the other subgroups stratified by age, sex, LV ejection fraction, baseline interstitial volume and body mass index (**Supplemental Table 3**).

Secondary Trial Endpoints

Compared to valsartan alone, sacubitril/valsartan resulted in greater reduction in indexed LV mass (-11.2±10.3 versus -6.3±5.2 g/m^2, P=0.010) and indexed myocyte volume (-8.4±7.9 versus -4.6±4.2 mL/m^2, P=0.010). Sacubitril/valsartan also led to a greater decrease in indexed LA volume (-9.8±8.7 versus -5.0±8.0 mL/m^2, P=0.013) and LV filling pressures (-1.8±1.5 versus -0.9±1.1 mmHg, P=0.003) compared to valsartan, suggestive of improved diastolic function.

There were no significant differences in changes in cardiac volumes, systolic function, and other measures of myocardial mechanics between the treatment groups. Although sacubitril/valsartan was associated with a statistically significant improvement in global longitudinal strain (GLS) compared to valsartan (-0.9±2.3 versus 0.2±1.9, P=0.027), the effect size was small and the isolated improvement in GLS was not associated with improvement in the other strain components (**Table 2**). Similar findings were observed when

NUS Restricted

relevant CMR metrics were indexed to body surface area (**Supplemental Table 4**). Compared to valsartan, sacubitril/valsartan was associated with a significant reduction from baseline to 52 weeks in NT-proBNP (ETR=0.72; 95% CI: 0.54–0.91; P=0.006) and hsTnT (ETR=0.83; 95% CI: 0.69–0.99; P=0.005).

Treatment Effects on Blood Pressure Control

Participants in both groups achieved similarly lowered 24h mean BP at all timepoints assessed in the trial (**Figure 3**). At the end of 52 weeks, the 24h mean SBP was 125±11 mmHg with sacubitril/valsartan versus 126±11 mmHg with valsartan (P=0.762 for comparison). This corresponded to a decrease of 13.3±13.1 and 10.6±13.4 mmHg from baseline in the sacubitril/valsartan and valsartan groups, respectively. Treatment difference between the two groups was not significant (-2.7 [95% CI: -8.7 to 3.3] mmHg, P=0.379).

Similarly, the 24h mean DBP at the end of study was 75±9 mmHg with sacubitril/valsartan versus 75±12 mmHg with valsartan (P=0.943 for comparison), corresponding to a decrease of 7.1±7.1 and 5.6±9.6 mmHg from baseline in the two respective treatment groups. The treatment difference in 24h DBP reduction between the two groups was also not significant (-1.5 [95% CI: -5.4 to 2.3] mmHg, P=0.426).

Adverse Events

Treatment with sacubitril/valsartan and valsartan were very well-tolerated in this trial. One patient developed nocturnal cough with sacubitril/valsartan three months after randomization. Symptoms improved upon dose reduction, and the participant continued with the trial. Renal function remained stable throughout the trial (**Table 3**). There were no major adverse

NUS Restricted

cardiovascular events such as hospitalizations for HF, myocardial infarction, strokes and deaths reported during the trial.

DISCUSSION

The main finding of REVERSE-LVH was that sacubitril/valsartan resulted in superior reduction in diffuse interstitial fibrosis in hypertensive patients with LVH following 52 weeks of treatment compared to valsartan alone. This was accompanied by a greater decrease in LV mass and improvement in diastolic function. There was no significant difference in systolic function improvement between the two treatment groups (**Figure 4**).

Cardiovascular Magnetic Resonance Measures of Myocardial Fibrosis

The use of CMR in REVERSE-LVH has allowed reliable quantification of fibrosis without invasive endomyocardial biopsies, a procedure that was required in previous studies on anti-fibrotic therapies[20–23]. Novel CMR mapping techniques have dramatically advanced tissue characterization non-invasively, allowing us to investigate novel anti-fibrotic therapies in diverse populations.

ECV fraction represents the ratio of interstitium to the total myocardial volume. Although it is widely used to measure diffuse interstitial fibrosis, its utility may be limited where treatments affect both myocyte and interstitial compartments. In such cases, therapies that reduce both compartments may lead to an unchanged or even increased ECV fraction. For instance, in REVERSE-LVH, despite reductions in interstitial and myocyte volumes, both treatment groups showed a slight increase in ECV fraction, likely due to a greater reduction in myocyte volume relative to interstitial volume. Instead, deeper mechanistic insights can be

NUS Restricted

accomplished by separately assessing the interstitial and myocyte compartments, particularly for novel treatments or interventions with potential effects on both compartments.

Anti-Hypertensive Therapies to Target Myocardial Fibrosis

Myocardial fibrosis is a hallmark of HF, and not all BP medications have anti-fibrotic properties. Among conventional anti-hypertensive therapies, ACEIs or ARBs that target the RAAS have shown the most promise in regressing biopsy-confirmed myocardial fibrosis in HHD, independent of BP lowering effects[20,21,24]. Similarly, mineralocorticoid receptor antagonists (MRAs) like spironolactone and eplerenone reduce serum markers of collagen turnover and improve diastolic function on echocardiography[25–27].

Sacubitril/valsartan, a first-in-class ARNI used primarily for HFrEF, is also an effective anti-hypertensive medication[28]. While sacubitril/valsartan is approved for hypertension in some countries[29], its effectiveness in regressing myocardial fibrosis in patients with hypertension has not been established. Through the REVERSE-LVH trial using CMR to assess interstitial volume, sacubitril/valsartan demonstrated a two-fold greater reduction in diffuse interstitial fibrosis compared to valsartan alone. Both treatment groups achieved similar BP throughout the trial, an important feature to isolate the anti-fibrotic effects of sacubitril/valsartan from any potential influence of BP control. It is also noteworthy that the other classes of anti-hypertensive medications prescribed were similar between the two treatment groups.

Sacubitril/valsartan also led to greater LV mass regression compared to valsartan alone, findings that align with results from a previous trial comparing sacubitril/valsartan and olmesartan[30]. Overall, these results reinforced the beneficial impact of sacubitril/valsartan on reverse remodeling in patients with HHD.

NUS Restricted

REVERSE-LVH in the Context of HFpEF Trials

PARAGON-HF (Prospective Comparison of ARNI with ARB Global Outcomes in HF with Preserved Ejection Fraction) reported that sacubitril/valsartan did not result in significantly lower rates of HF hospitalizations and cardiovascular deaths in patients with HF and preserved ejection fraction (HFpEF) compared to valsartan[31]. Considering these results, it is important to discuss the relevance of REVERSE-LVH after PARAGON-HF and possible implications for future HFpEF trials.

HFpEF represents a syndrome characterized by phenotypic heterogeneity, underpinned by complex underlying mechanisms, and contributed by various coexisting comorbidities. This heterogeneity is exemplified by the observation that despite similar E/e' (echocardiographic marker of LV filling pressure), the prevalence of LVH ranges between 14 and 50% in recent HFpEF trials (21% in PARAGON-HF)[32]. This observation hints at the presence of additional factors contributing to elevated LV filling pressure (such as chronic lung disease, atrial fibrillation and/or chronic kidney disease). Consequently, it is plausible that not all these patients had derived the anticipated benefits from the HF medications being investigated.

To enhance the effectiveness of future HFpEF trials, one key consideration lies in the strategic inclusion of patients with common phenotypes driving the underlying pathophysiology. This approach will enable more precise selection of pharmaceutical therapies tailored at specific mechanistic phenotypes[33,34]. For instance, pirfenidone, a small-molecule anti-fibrotic agent without hemodynamic effects, reduced myocardial fibrosis in patients with HFpEF[35]. This reduction in interstitial space without significance changes in myocyte compartment explains for the overall decrease in ECV fraction. In contrast,

NUS Restricted

sacubitril/valsartan reduces both myocardial fibrosis and hypertrophy because of its effects on hemodynamics, natriuretic and RAAS system.

Clinical Implications of REVERSE-LVH

The effectiveness of hypertension treatment is often assessed by the BP targets achieved, with the fundamental goal to minimize end-organ complications such as HF. However, cardiac remodeling in the hypertensive heart is complex and the peripheral BP may not adequately reflect the abnormalities in the myocardium. A moderate correlation was demonstrated between interstitial volume and 24h SBP ($r=0.36$, $P<0.001$), worse with office SBP ($r=0.21$; $P<0.01$)[15]. In an unpublished analysis of REMODEL, about 54% of 224 hypertensive participants with LVH had 24h SPB <140mmHg. This poses a challenge in defining the optimal BP targets in hypertensive patients with LVH, particularly if BP are adequately controlled.

Because the apparent amelioration of diffuse interstitial fibrosis is associated with improved outcomes, the interstitium is an attractive target for drug repurposing and development[4,36,37]. Sacubitril/valsartan demonstrated superior efficacy than valsartan alone in decreasing diffuse interstitial fibrosis after 52 weeks of treatment. The observed association with improved diastolic function was encouraging and may suggest that a longer treatment duration was needed to reverse a long-standing process before an improvement in systolic function becomes evident.

The findings from REVERSE-LVH strengthened the case for considering sacubitril/valsartan in selected individuals with hypertensive LVH, especially those who failed to achieve adequate reduction in diffuse interstitial fibrosis with ACEIs or ARBs. Individuals with 24h

NUS Restricted

SBP greater than 135mmHg (median SBP in this study) may have further reduction in diffuse interstitial fibrosis with sacubitril/valsartan but this finding from the post-hoc subgroup analysis was exploratory and should be investigated in future trials.

Study Strengths and Limitations

It was by chance that a higher proportion of female participants (59%) were recruited. Despite the challenges posed by COVID-19 between 2020 and 2021, the trial had very low dropout rates (5%) and exceptionally high treatment adherence rates, surpassing the 80% threshold widely used to define "good adherence"[38]. Both treatment arms achieved similar BP reduction at the end of the trial. These observations highlighted the meticulous conduct of the trial.

The study had some limitations. Due to the relatively modest sample size, numerous variables could not be incorporated into statistical adjustment. As baseline comparability between the two treatment groups was achieved through randomization, statistical adjustment was intended to further enhance the reliability of the findings. Two participants (one in each treatment group) were given MRAs, which may confound regression of diffuse interstitial fibrosis. This was inevitable because their BPs were not optimally controlled despite being prescribed the maximum tolerated doses of trial medications and other classes of anti-hypertensives. Natriuretic peptides and circulating markers of fibrosis and collagen turnover have not been included in this study. However, they will be analyzed and reported in subsequent studies. REVERSE-LVH was adequately powered as a phase 2 trial. However, the relatively small sample size was insufficient to assess the effects on clinical endpoints in patients with hypertensive LVH. Future trials with larger cohorts are needed to evaluate the impact of diffuse fibrosis regression on clinical outcomes.

NUS Restricted

Conclusion

In patients with hypertensive LVH, sacubitril/valsartan demonstrated superior efficacy in reducing diffuse interstitial fibrosis compared to valsartan, independent of BP control. This was accompanied by a decrease in LV mass and improvement in diastolic function. These findings suggested an important potential for regressing diffuse interstitial fibrosis in patients with hypertensive LVH through accessible and well-tolerated pharmacological interventions, beyond BP control.

Acknowledgements

The authors wish to thank all the study participants, the radiographers at the Department of Cardiovascular Magnetic Resonance, the pharmacists at the Department of Pharmacy and the research coordinators at the Clinical Trial Research Office, National Heart Centre Singapore for their assistance in the study.

Disclosures

Prof. Lam has received consulting fees from Novartis. Prof. Butler is a consultant to Novartis. The other authors do not have any relevant conflicts of interest to disclose.

Funding

REVERSE-LVH is funded by the National Medical Research Council of Singapore (MOH-CTGIIT17may-0001).

NUS Restricted

REFERENCES

1. Goldberg LR, Jessup M. Stage B heart failure: management of asymptomatic left ventricular systolic dysfunction. *Circulation*. 2006;113(24):2851-2860.

2. Mohebi R, Wang D, Lau ES, et al. Effect of 2022 ACC/AHA/HFSA criteria on stages of heart failure in a pooled community cohort. *J Am Coll Cardiol*. 2023;81(23):2231-2242.

3. Messerli FH, Rimoldi SF, Bangalore S. The transition from hypertension to heart failure: contemporary update. *JACC Heart Fail*. 2017;5(8):543-551.

4. González A, López B, Ravassa S, et al. Myocardial Interstitial fibrosis in hypertensive heart disease: from mechanisms to clinical management. *Hypertens Dallas Tex 1979*. 2024;81(2):218-228.

5. González A, Schelbert EB, Díez J, Butler J. Myocardial interstitial fibrosis in heart failure. *J Am Coll Cardiol*. 2018;71(15):1696-1706.

6. Ruilope LM, Dukat A, Böhm M, Lacourcière Y, Gong J, Lefkowitz MP. Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study. *Lancet Lond Engl*. 2010;375(9722):1255-1266.

7. McMurray JJV, Packer M, Desai AS, et al. Angiotensin–neprilysin inhibition versus enalapril in heart failure. *N Engl J Med*. 2014;371(11):993-1004.

8. Suematsu Y, Miura S, Goto M, et al. LCZ696, an angiotensin receptor-neprilysin inhibitor, improves cardiac function with the attenuation of fibrosis in heart failure with reduced ejection fraction in streptozotocin-induced diabetic mice. *Eur J Heart Fail*. 2016;18(4):386-393.

NUS Restricted

9. Burke RM, Lighthouse JK, Mickelsen DM, Small EM. Sacubitril/Valsartan decreases cardiac fibrosis in left ventricle pressure overload by restoring pkg signaling in cardiac fibroblasts. *Circ Heart Fail*. 2019;12(4):e005565.

10. Chin CWL, Everett RJ, Kwiecinski J, et al. Myocardial fibrosis and cardiac decompensation in aortic stenosis. *JACC Cardiovasc Imaging*. 2017;10(11):1320-1333.

11. Lee V, Zheng Q, Toh DF, et al. Sacubitril/valsartan versus valsartan in regressing myocardial fibrosis in hypertension: a prospective, randomized, open-label, blinded endpoint clinical trial protocol. *Front Cardiovasc Med*. 2023;10:1248468.

12. Le TT, Tan RS, De Deyn M, et al. Cardiovascular magnetic resonance reference ranges for the heart and aorta in Chinese at 3T. *J Cardiovasc Magn Reson*. 2016;18(1):21.

13. Weber MA, Schiffrin EL, White WB, et al. Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. *J Clin Hypertens*. 2014;16(1):14-26.

14. Ministry of Health, Singapore. *MOH clinical practice guidelines on hypertension 1/2017*. Ministry of Health, Singapore; 2017. https://www.moh.gov.sg/docs/librariesprovider4/guidelines/cpg_hypertension-booklet---nov-2017.pdf

15. Goh VJ, Le TT, Bryant J, et al. Novel Index of maladaptive myocardial remodeling in hypertension. *Circ Cardiovasc Imaging*. 2017;10(9):e006840.

NUS Restricted

16. Iyer NR, Le TT, Kui MSL, et al. Markers of focal and diffuse nonischemic myocardial fibrosis are associated with adverse cardiac remodeling and prognosis in patients with hypertension: the REMODEL study. *Hypertens Dallas Tex 1979*. 2022;79(8):1804-1813.

17. Le TT, Lim V, Ibrahim R, et al. The remodelling index risk stratifies patients with hypertensive left ventricular hypertrophy. *Eur Heart J - Cardiovasc Imaging*. 2021;22(6):670-679.

18. Holm H, Magnusson M, Jujić A, Bozec E, Girerd N. How to calculate ventricular–arterial coupling? *Eur J Heart Fail*. 2022;24(4):600-602.

19. Garg P, Gosling R, Swoboda P, et al. Cardiac magnetic resonance identifies raised left ventricular filling pressure: prognostic implications. *Eur Heart J.* 2022;43(26):2511-2522.

20. Brilla CG, Funck RC, Rupp H. Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease. *Circulation*. 2000;102(12):1388-1393.

21. Díez J, Querejeta R, López B, González A, Larman M, Martínez Ubago JL. Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients. *Circulation.* 2002;105(21):2512-2517.

22. López B, Querejeta R, González A, Sánchez E, Larman M, Díez J. Effects of loop diuretics on myocardial fibrosis and collagen type I turnover in chronic heart failure. *J Am Coll Cardiol*. 2004;43(11):2028-2035.

23. Izawa H, Murohara T, Nagata K, et al. Mineralocorticoid receptor antagonism ameliorates left ventricular diastolic dysfunction and myocardial fibrosis in mildly

NUS Restricted

symptomatic patients with idiopathic dilated cardiomyopathy: a pilot study. *Circulation*. 2005;112(19):2940-2945.

24. López B, Querejeta R, Varo N, et al. Usefulness of serum carboxy-terminal propeptide of procollagen type I in assessment of the cardioreparative ability of antihypertensive treatment in hypertensive patients. *Circulation*. 2001;104(3):286-291.

25. Mak GJ, Ledwidge MT, Watson CJ, et al. Natural history of markers of collagen turnover in patients with early diastolic dysfunction and impact of eplerenone. *J Am Coll Cardiol*. 2009;54(18):1674-1682.

26. Kosmala W, Przewlocka-Kosmala M, Szczepanik-Osadnik H, Mysiak A, O'Moore-Sullivan T, Marwick TH. A randomized study of the beneficial effects of aldosterone antagonism on LV function, structure, and fibrosis markers in metabolic syndrome. *JACC Cardiovasc Imaging*. 2011;4(12):1239-1249.

27. Kosmala W, Przewlocka-Kosmala M, Szczepanik-Osadnik H, Mysiak A, Marwick TH. Fibrosis and cardiac function in obesity: a randomised controlled trial of aldosterone blockade. *Heart*. 2013;99(5):320-326.

28. Bavishi C, Messerli FH, Kadosh B, Ruilope LM, Kario K. Role of neprilysin inhibitor combinations in hypertension: insights from hypertension and heart failure trials. *Eur Heart J*. 2015;36(30):1967-1973.

29. Loo G, Puar T, Foo R, et al. Unique characteristics of Asians with hypertension: what is known and what can be done? *J Hypertens*. 2024;42(9):1482-1489.

30. Schmieder RE, Wagner F, Mayr M, et al. The effect of sacubitril/valsartan compared to olmesartan on cardiovascular remodelling in subjects with essential hypertension: the

NUS Restricted

results of a randomized, double-blind, active-controlled study. *Eur Heart J*. 2017;38(44):3308-3317.

31. Solomon SD, McMurray JJV, Anand IS, et al. Angiotensin–neprilysin inhibition in heart failure with preserved ejection fraction. *N Engl J Med*. 2019;381(17):1609-1620.

32. Shah AM, Cikes M, Prasad N, et al. Echocardiographic features of patients with heart failure and preserved left ventricular ejection fraction. *J Am Coll Cardiol*. 2019;74(23):2858-2873.

33. Palazzuoli A, Caravita S, Paolillo S, et al. Current gaps in HFpEF trials: Time to reconsider patients' selection and to target phenotypes. *Prog Cardiovasc Dis*. 2021;67:89-97.

34. Sweeney M, Corden B, Cook SA. Targeting cardiac fibrosis in heart failure with preserved ejection fraction: mirage or miracle? *EMBO Mol Med*. 2020;12(10):e10865.

35. Lewis GA, Dodd S, Clayton D, et al. Pirfenidone in heart failure with preserved ejection fraction: a randomized phase 2 trial. *Nat Med*. 2021;27(8):1477-1482.

36. Schelbert EB, Fonarow GC, Bonow RO, Butler J, Gheorghiade M. Therapeutic targets in heart failure: refocusing on the myocardial interstitium. *J Am Coll Cardiol*. 2014;63(21):2188-2198.

37. Schelbert EB, Butler J, Diez J. Why clinicians should care about the cardiac interstitium. *JACC Cardiovasc Imaging*. 2019;12(11 Pt 2):2305-2318.

38. Haynes RB, Taylor DW, Sackett DL, Gibson ES, Bernholz CD, Mukherjee J. Can simple clinical measurements detect patient noncompliance? *Hypertens Dallas Tex 1979*. 1980;2(6):757-764.

NUS Restricted

627

NUS Restricted

FIGURE LEGENDS

Figure 1. Participant Recruitment, Randomization and Treatment

A total of 78 participants were randomized in the trial. One patient in the sacubitril/valsartan group withdrew at week 4 due to concerns of medication side effects. One patient in the valsartan group withdrew at week 26 due to difficulties with trial commitment. This participant had final visit investigations (including cardiovascular magnetic resonance) performed at time of withdrawal, according to study protocol. Primary and secondary endpoints were analyzed as intention-to-treat in all 78 participants.



Figure 2. Effects of Sacubitril/valsartan Compared to Valsartan on Primary Endpoint

The primary endpoint before and after adjustment for baseline covariates. (A) Unindexed interstitial volume. (B) Interstitial volume indexed to body surface area. Values are mean (95% confidence interval).



Figure 3. Blood Pressure Control Between Sacubitril/valsartan and Valsartan

The mean blood pressure assessed at all timepoints during the trial were similar between the two treatment groups. Vertical bars are mean (95% confidence interval). Values are P value for between-group comparison.



Figure 4. Central Illustration

Study design and findings of REVERSE-LVH, a randomized phase 2 trial to compare the efficacy between sacubitril/valsartan and valsartan in regressing diffuse interstitial fibrosis in hypertensive patients with left ventricular hypertrophy (LVH). CMR = cardiovascular magnetic resonance; LV = left ventricular; LA = left atrial.



Table 1. Baseline Characteristics of All Randomized Participants

	All Participants (n=78)	Sacubitril/ valsartan (n=39)	Valsartan (n=39)
Baseline Clinical Characteristics			
Age, y	58±11	56±11	59±11
Males, n (%)	32 (41)	18 (46)	14 (36)
Chinese ethnicity, n (%)	71 (91)	35 (90)	36 (92)
Weight, kg	71±18	74±19	68±16
Body mass index, kg/m^2	27.2±5.6	27.7±6.2	26.7±5.1
Dyslipidemia, n (%)	33 (42)	18 (46)	15 (39)
Diabetes mellitus, n (%)	14 (18)	9 (23)	5 (13)
Smoking, n (%)	6 (8)	3 (8)	3 (8)
24h systolic blood pressure, mmHg	137±14	138±17	137±10
24h diastolic blood pressure, mmHg	81±11	82±11	80±11
Baseline Biochemical Characteristics			
Potassium, mmol/L	3.8 [3.6, 4.0]	3.8 [3.6, 4.0]	3.7 [3.6, 4.0]
Creatinine, µmol/L	72 [52, 86]	73 [51, 88]	72 [54, 85]
NT-proBNP, pg/mL	53 [28, 141]	42 [28, 101]	60 [31, 275]
High sensitivity cTnT, pg/mL	9.8 [6.5, 14.5]	9.5 [6.6, 15.0]	10.9 [6.0, 14.5]
Estimated GFR, mL/min/1.73 m^{2a}	90 [72, 106]	94 [74, 108]	88 [70, 102]
Baseline Cardiovascular Magnetic Resonance Characteristics			
Indexed LV mass, g/m^2	64±19	64±19	64±18
Indexed LV end diastolic volume, mL/m^2	78±15	76±16	79±15
Indexed LV end systolic volume, mL/m^2	32±12	32±13	32±11
Indexed LV stroke volume, mL/m^2	46±7	45±8	47±7
LV ejection fraction	60±9	59±10	60±7
Indexed RV end diastolic volume, mL/m^2	74±13	73±13	74±13
Indexed RV end systolic volume, mL/m^2	28±10	28±9	27±11
Indexed RV stroke volume, mL/m^2	46±7	45±8	47±7
RV ejection fraction	63±9	62±8	64±9
Indexed left atrial volume, mL/m^2	55±15	53±12	56±18
Indexed right atrial area, cm^2/m^2	12.0±2.1	11.7±1.8	12.4±2.2
Remodeling Index	5.33±0.99	5.22±0.80	5.44±1.15
Ventricular-arterial coupling ratio	0.71±0.29	0.74±0.36	0.69±0.22
Estimated LV filling pressure, mmHg	15.6±2.8	15.7±3.0	15.5±2.6
Maximal wall thickness, mm	10.0±2.4	10.1±2.1	9.9±2.7
Mean wall thickness, mm	7.5±1.6	7.7±1.6	7.4±1.6
LV mass/end-diastolic volume ratio	0.83±0.17	0.84±0.14	0.81±0.19

NUS Restricted

Global longitudinal strain, %	-16.5±3.3	-16.0±3.3	-17.0±3.2
Global circumferential strain, %	-18.7±3.2	-18.2±3.5	-19.1±2.8
Global radial strain, %	32.4±8.6	31.2±9.2	33.6±7.8
Extracellular volume fraction, %	26.4±2.6	26.1±2.4	26.8±2.8
Indexed myocyte volume, mL/m^2	45.0±13.1	45.4±13.7	44.5±12.6
Non ischemic late gadolinium enhancement, n (%)	29 (37)	15 (38)	14 (36)

Values are mean±SD or median [interquartile range] unless otherwise indicated. [a]Estimated GFR calculated using MDRD equation = 175 x [serum creatinine (µmol/L)/88.4]$^{-1.154}$ × (age)$^{-0.203}$ × (0.742 if female). Left ventricular hypertrophy was defined based on age- and sex-specific reference ranges established in the local population (females: 47g/m^2 and males: 65g/m^2). Abnormal global longitudinal strain in the population was defined as < -14.0 to -15.0% in males and < -17.0 to -18.0% in females[20].

GFR = glomerular filtration rate; LV = left ventricular; RV = right ventricular; NT-proBNP = N-terminal pro-B-type natriuretic peptide; cTnT = cardiac troponin T

NUS Restricted

668 **Table 2. Secondary Endpoints After 52 Weeks of Treatment**

	At End of 52 Weeks of Treatment		Change from Baseline to Post-treatment		Treatment Difference	
	Sacubitril/valsartan	**Valsartan**	**Sacubitril/valsartan**	**Valsartan**	**95% Confidence Interval**	**P Value**
Indexed LV mass, g/m^2	53±14	58±20	-11.2±10.3	-6.3±5.2	**-8.6 to -1.2**	**0.010**
Indexed LV end diastolic volume, mL/m^2	70±12	75±17	-6.4±8.8	-4.1±8.6	-6.2 to 1.6	0.247
Indexed LV end systolic volume, mL/m^2	28±8	29±15	-4.1±8.9	-3.1±8.0	-4.8 to 2.9	0.622
Indexed LV stroke volume, mL/m^2	42±7	46±7	-2.4±5.0	-1.1±5.6	-3.7 to 1.0	0.263
LV ejection fraction	61±7	62±8	1.2±6.5	2.1±6.2	-3.8 to 1.9	0.511
Indexed RV end diastolic volume, mL/m^2	69±12	72±12	-3.8±6.0	-2.7±9.6	-4.8 to 2.4	0.520
Indexed RV end systolic volume, mL/m^2	27±8	26±9	-1.2±5.6	-1.4±7.7	-2.9 to 3.2	0.925
Indexed RV stroke volume, mL/m^2	42±7	46±8	-2.6±4.7	-1.3±7.3	-4.1 to 1.5	0.349
RV ejection fraction	62±8	64±10	-0.3±6.3	0.1±8.3	-3.7 to 2.9	0.811
Indexed left atrial volume, mL/m^2	43±11	51±17	-9.8±8.7	-5.0±8.0	**-8.5 to -1.0**	**0.013**
Indexed right atrial area, cm^2/m^2	10.8±1.8	11.7±2.0	-0.8±1.4	-0.7±1.3	-0.7 to 0.5	0.772
LV mass/end-diastolic volume ratio	0.76±0.14	0.77±0.20	-0.08±0.09	-0.04±0.09	-0.08 to 0.00	0.072
Remodeling Index	5.69±0.89	5.82±1.34	0.46±0.56	0.38±0.50	-0.17 to 0.31	0.544
Ventricular-arterial coupling ratio	0.67±0.21	0.64±0.34	-0.07±0.26	-0.04±0.23	-0.14 to 0.09	0.655
Estimated LV filling pressure, mmHg	13.8±2.3	14.6±2.7	-1.8±1.5	-0.9±1.1	**-1.5 to -0.3**	**0.003**
Maximal wall thickness, mm	9.0 ± 1.7	9.1±2.7	-1.1±1.0	-0.7±0.7	-0.8 to 0.0	0.065

NUS Restricted

Global longitudinal strain, %	-17.0±2.5	-16.8±3.3	-0.9±2.3[a]	0.2±1.9	**-2.0 to -0.1**	**0.027**
Global circumferential strain, %	-18.9±2.6	-19.1±2.8	-0.6±2.2[a]	-0.03±1.9[a]	-1.5 to 0.4	0.253
Global radial strain, %	33.1±7.6	33.4±7.1	1.7±6.5	-0.2±5.8	-0.9 to 4.7	0.189
Extracellular volume fraction, %	26.4±2.6	27.1±2.8	0.3±2.0	0.3±2.7	-1.1 to 1.1	0.962
Indexed myocyte volume, mL/m^2	37.2±9.7	39.9±13.4	-8.4±7.9	-4.6±4.2	**-2.3 to -0.4**	**0.010**

[a]Negative value signifies an improvement in strain.
LV = left ventricular; RV = right ventricular.
Values are mean±SD

NUS Restricted

Table 3. Renal Function Between Treatment Groups Throughout Study Trial

	Week	Sacubitril/ valsartan	Valsartan	P value
Potassium, mmol/L	**0**	3.8 [3.6, 4.0]	3.7 [3.6, 4.0]	0.800
	4	3.9 [3.7, 4.3]	4.0 [3.7, 4.3]	0.778
	8	4.0 [3.8, 4.2]	4.0 [3.9, 4.2]	0.766
	26	4.1 [3.7, 4.5]	4.1 [3.9, 4.3]	0.765
	52	3.9 [3.6, 4.2]	3.8 [3.5, 4.2]	0.602
Estimated GFR, mL/min/1.73m^2	**0**	94 [74, 108]	88 [70, 102]	0.420
	4	82 [68, 108]	84 [74, 100]	0.996
	8	86 [71, 102]	82 [63, 110]	0.909
	26	89 [65, 107]	84 [70, 97]	0.897
	52	89 [63, 104]	83 [69, 100]	0.796

Values are median [inter-quartile range]. Values between treatment groups were compared with Mann-Whitney U test. GFR = glomerular filtration rate.